PDGFRα in liver pathophysiology: Emerging roles in development, regeneration, fibrosis, and cancer

Gene Expression

Volumn 16, Issue 3, 2015, Pages 109-127

  Kikuchi, Alexander ^a   Monga, Satdarshan Pal ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

APA5; Cholangiocarcinoma; Cirrhosis; Hepatic fibrosis; Hepatocellular carcinoma; IMC 3G3; Liver development; Liver regeneration; NF B; Oxidative stress; Platelet derived growth factor (PDGF); Sorafenib; Transforming growth factor (TGF ); Catenin

Indexed keywords

BETA CATENIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OLARATUMAB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ANGIOGENESIS; BILE DUCT CARCINOMA; CELL ACTIVATION; CELLULAR DISTRIBUTION; CHOLESTASIS; EPITHELIAL MESENCHYMAL TRANSITION; HEMATOPOIETIC STEM CELL; HUMAN; LIGAND BINDING; LIVER CANCER; LIVER CIRRHOSIS; LIVER DEVELOPMENT; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; LIVER REGENERATION; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CELL DIFFERENTIATION; CELL PROLIFERATION; GENETICS; LIVER; LIVER TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PATHOPHYSIOLOGY;

CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER REGENERATION; MOLECULAR TARGETED THERAPY; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SIGNAL TRANSDUCTION;

EID: 84928403301     PISSN: 10522166     EISSN: None     Source Type: Journal    
DOI: 10.3727/105221615X14181438356210     Document Type: Review

References (136)

1. Action Plan for Liver Disease research: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); 2004.
2. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115:209-218.
3. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu rev Pathol 2011; 6:425-456.
4. Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. J Hepatol 2012; 56:1171-1180.
5. Friedman SL, Bansal MB. Reversal of hepatic fibrosis-Fact or fantasy? Hepatology 2006; 43:S82-88.
6. Farazi PA, DePinho rA Hepatocellular carcinoma patho-genesis: From genes to environment. Nat rev Cancer 2006; 6:674-687.
7. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut 2014; 63: 844-855.
8. Wong L, Yamasaki G, Johnson rJ, Friedman SL. Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest 1994; 94:1563-1569.
9. Bonner J. regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor rev 2004; 15: 255-273.
10. Andrae J, Gallini R, Betsholtz C. role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22:1276-1312.
11. Heldin CH, Ostman A, Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1998; 1378:F79-113.
12. Birge RB, Kalodimos C, Inagaki F, Tanaka S. Crk and CrkL adaptor proteins: Networks for physiological and pathological signaling. Cell Commun Signal 2009; 7:13.
13. Eriksson A, Nanberg E, Ronnstrand L, Engstrom U, Hellman U, Rupp E, et al. Demonstration of functionally different interactions between phospholipase C-gamma and the two types of platelet-derived growth factor receptors. J Biol Chem 1995; 270:7773-7781.
14. Chen PH, Chen X, He X. Platelet-derived growth factors and their receptors: Structural and functional perspectives. Biochim Biophys Acta 2013; 1834:2176-2186.
15. Bishayee S, Majumdar S, Khire J, Das M. Ligand-induced dimerization of the platelet-derived growth factor receptor. Monomer-dimer interconversion occurs independent of receptor phosphorylation. J Biol Chem 1989; 264:11699-11705.
16. Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor rev 2004; 15:205-213.
17. Ekman S, Thuresson ER, Heldin CH, Rönnstrand L. Increased mitogenicity of an alphabetaheterodimeric PDGF receptor complex correlates with lack of rasGAP binding. Oncogene 1999; 18:2481-2488.
18. Soriano P. The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development 1997; 124:2691-2700.
19. Soriano P. Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. Genes Dev 1994; 8:1888-1896.
20. Ito K, Yanagida A, Okada K, Yamazaki Y, Nakauchi H, Kamiya A. Mesenchymal progenitor cells in mouse foetal liver regulate differentiation and proliferation of hepato-blasts. Liver Int 2013.
21. Diarmaid DH, Yo M, Satoru M, Kunimichi N, Daisuke A, Sadafumi S, et al. Isolation of mouse mesenchymal stem cells on the basis of expression of Sca-1 and PDGFr-a. Nat Protoc 2012; 7:2103-2111.
22. Toshitaka H, Hideaki F, Tetsuro H, Kentaro Y, Hisaya A, Shinji B, et al. Thy1-positive mesenchymal cells promote the maturation of CD49f-positive hepatic progenitor cells in the mouse fetal liver. Hepatology 2004; 39.
23. Li WL, Yamada Y, Ueno M, Nishikawa S, Nishikawa S, Takakura N. Platelet derived growth factor receptor alpha is essential for establishing a microenvironment that supports definitive erythropoiesis. J Biochem 2006; 140:267-273.
24. Awuah PK, Nejak-Bowen KN, Monga SP. Role and regulation of PDGFralpha signaling in liver development and regeneration. Am J Pathol 2013; 182:1648-1658.
25. Stock P, Monga D, Tan X, Micsenyi A, Loizos N, Monga SP Platelet-derived growth factor receptor-alpha: A novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther 2007; 6:1932-1941.
26. Li B, Zheng Y-W, Sano Y, Taniguchi H. Evidence for mesenchymal-epithelial transition associated with mouse hepatic stem cell differentiation. PLoS One 2011; 6.
27. Tanaka M, Okabe M, Suzuki K, Kamiya Y, Tsukahara Y, Saito S, Miyajima A. Mouse hepatoblasts at distinct developmental stages are characterized by expression of EpCAM and DLK1: Drastic change of EpCAM expression during liver development. Mech Dev 2009; 126.
28. Goldman O, Han S, Sourrisseau M, Dziedzic N, Hamou W, Corrneo B, et al. KDr identifies a conserved human and murine hepatic progenitor and instructs early liver development. Cell Stem Cell 2013; 12:748-760.
29. Asahina K, Tsai SY, Li P, Ishii M, Maxson RE, Jr., Sucov HM, Tsukamoto H. Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells during mouse liver development. Hepatology 2009; 49:998-1011.
30. Michalopoulos GK. Liver regeneration. J Cell Physiol 2007; 213:286-300.
31. Kang L-II, Mars WM, Michalopoulos GK. Signals and cells involved in regulating liver regeneration. Cells 2011; 1:1261-1292.
32. Paranjpe S, Bowen WC, Tseng GC, Luo J-HH, Orr A, Michalopoulos GK rNA interference against hepatic epidermal growth factor receptor has suppressive effects on liver regeneration in rats. Am J Pathol 2010; 176: 2669-2681.
33. Bowen WC, Michalopoulos AW, Orr A, Ding MQ, Stolz DB, Michalopoulos GK. Development of a chemically defined medium and discovery of new mitogenic growth factors for mouse hepatocytes: Mitogenic effects of FGF1/2 and PDGF. PLoS One 2014; 9:e95487.
34. Prosser CC, Yen rD, Wu J. Molecular therapy for hepatic injury and fibrosis: Where are we? World J Gastroenterol 2006; 12:509-515.
35. Brenner DA. Molecular pathogenesis of liver fibrosis. Trans Am Clin Climatol Assoc 2009; 120:361-368.
36. Friedman SL. Evolving challenges in hepatic fibrosis. Nat rev Gastroenterol Hepatol 2010; 7:425-436.
37. Constandinou C, Henderson N, Iredale JP. Modeling liver fibrosis in rodents. Methods Mol Med 2005; 117: 237-250.
38. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastro-enterology 2008; 134:1655-1669.
39. Oe H, Kaido T, Furuyama H, Mori A, Imamura M. Simultaneous transfer of vascular endothelial growth factor and hepatocyte growth factor genes effectively promotes liver regeneration after hepatectomy in cirrhotic rats. Hepatogastroenterology 2004; 51:1641-1647.
40. Suarez-Cuenca JA, Chagoya de Sanchez V, Aranda-Fraustro A, Sanchez-Sevilla L, Martinez-Perez L, Hernandez-Munoz R. Partial hepatectomy-induced regeneration accelerates reversion of liver fibrosis involving participation of hepatic stellate cells. Exp Biol Med (Maywood) 2008; 233:827-839.
41. Pinzani M, Milani S, Herbst H, DeFranco R, Grappone C, Gentilini A, et al. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am J Pathol 1996; 148: 785-800.
42. Borkham-Kamphorst E, Kovalenko E, van Roeyen CR, Gassler N, Bomble M, Ostendorf T, et al. Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury. Lab Invest 2008; 88:1090-1100.
43. Martin IV, Borkham-Kamphorst E, Zok S, van Roeyen CR, Eriksson U, Boor P, et al. Platelet-derived growth factor (PDGF)-C neutralization reveals differential roles of PDGF receptors in liver and kidney fibrosis. Am J Pathol 2013; 182:107-117.
44. Hayes BJ, Riehle KJ, Shimizu-Albergine M, Bauer RL, Hudkins KL, Johansson F, et al. Activation of platelet-derived growth factor receptor alpha contributes to liver fibrosis. PLoS One 2014; 9:e92925.
45. Borkham-Kamphorst E, Roeyen CRC, Ostendorf T, Floege J, Gressner AM, Weiskirchen R. Pro-fibrogenic potential of PDGF-D in liver fibrosis. J Hepatol 2007; 46:10641074.
46. Pinzani M, Knauss TC, Pierce GF, Hsieh P, Kenney W, Dubyak GR, Abboud HE. Mitogenic signals for platelet-derived growth factor isoforms in liver fat-storing cells. Am J Physiol 1991; 260:91.
47. Geremias AT, Carvalho MA, Borojevic R, Monteiro AN. TGF beta1 and PDGF AA Override collagen type I inhibition of proliferation in human liver connective tissue cells. BMC Gastroenterol 2004; 4:30.
48. Thieringer F, Maass T, Czochra P, Klopcic B, Conrad I, Friebe D, et al. Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-A. Gene 2008; 423:23-28.
49. Wu E, Palmer N, Tian Z, Moseman AP, Galdzicki M, Wang X, et al. Comprehensive dissection of PDGF-PDGFr signaling pathways in PDGFr genetically defined cells. PLoS One 2008.
50. Czochra P, Klopcic B, Meyer E, Herkel J, Garcia-Lazaro JF, Thieringer F, et al. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol 2006; 45:419-428.
51. Campbell JS, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, Haran AC, et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepato-cellular carcinoma. Proc Natl Acad Sci USA 2005; 102: 3389-3394.
52. Campbell JS, Johnson MM, Bauer rL, Hudkins KL, Gilbertson DG, riehle KJ, et al. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis. Differentiation 2007; 75:843-852.
53. Liu C, Li J, Xiang X, Guo L, Tu K, Liu Q, et al. PDGF receptor-alpha promotes TGF-beta signaling in hepatic stellate cells via transcriptional and posttranscriptional regulation of TGF-beta receptors. Am J Physiol Gastrointest Liver Physiol 2014; 307:G749-759.
54. Matsuzaki K. Smad phosphoisoform signals in acute and chronic liver injury: Similarities and differences between epithelial and mesenchymal cells. Cell Tissue res 2012; 347:225-243.
55. Yamakage A, Kikuchi K, Smith EA, Leroy EC, Trojanowska M. Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med 1992; 175: 1227-1234.
56. Lei H, Velez G, Kazlauskas A. Pathological signaling via platelet-derived growth factor receptor {alpha} involves chronic activation of Akt and suppression of p53. Mol Cell Biol 2011; 31:1788-1799.
57. Lei H, Kazlauskas A. A reactive oxygen species-mediated, self-perpetuating loop persistently activates platelet-derived growth factor receptor alpha. Mol Cell Biol 2014; 34:110-122.
58. Dolloff NG, Russell MR, Loizos N, Fatatis A. Human bone marrow activates the Akt pathway in metastatic prostate cells through transactivation of the alpha-platelet-derived growth factor receptor. Cancer res 2007; 67:555-562.
59. Russell MR, Liu Q, Fatatis A. Targeting the {alpha} receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis. Clin Cancer res 2010; 16:5002-5010.
60. Baghy K, Horvath Z, Regos E, Kiss K, Schaff Z, Iozzo RV, Kovalszky I. Decorin interferes with platelet-derived growth factor receptor signaling in experimental hepato-carcinogenesis. FEBS J 2013; 280:2150-2164.
61. Breitkopf K, Roeyen C, Sawitza I, Wickert L, Floege J, Gressner AM. Expression patterns of PDGF-A, -B, -C and -D and the PDGF-receptors alpha and beta in activated rat hepatic stellate cells (HSC). Cytokine 2005; 31:349-357.
62. Yoshida K, Matsuzaki K, Mori S, Tahashi Y, Yamagata H, Furukawa F, et al. Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am J Pathol 2005; 166:1029-1039.
63. Battegay EJ, raines EW, Seifert rA, Bowen-Pope DF, Ross R. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 1990; 63:515-524.
64. Keiko I, Chunyan J, Mingjun Z, Min C, Thomas Joseph M-M, Tae Jun P, et al. Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci 2014; 111:305.
65. Kinnman N, Francoz C, Barbu V, Wendum D, rey C, Hultcrantz R, et al. The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest 2003; 83:163-173.
66. Wells rG, Kruglov E, Dranoff JA. Autocrine release of TGF-beta by portal fibroblasts regulates cell growth. FEBS Lett 2004; 559:107-110.
67. Zhaodong L, Jonathan AD, Erick PC, Masayuki U, Jean S, Rebecca GW. Transforming growth factor-b and substrate stiffness regulate portal fibroblast activation in culture. Hepatology 2007; 46(4):1246-1256.
68. Borkham-Kamphorst E, Herrmann J, Stoll D, Treptau J, Gressner AM, Weiskirchen R. Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab Invest 2004; 84: 766-777.
69. Zhang T, Sun HC, Xu Y, Zhang KZ, Wang L, Qin LX, et al. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin Cancer res 2005; 11:8557-8563.
70. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009; 15:21-34.
71. Neubauer K, ritzel A, Saile B, ramadori G. Decrease of platelet-endothelial cell adhesion molecule 1-gene-expression in inflammatory cells and in endothelial cells in the rat liver following CCl4-administration and in vitro after treatment with TNFα. Immunol Lett 2000; 74:153164.
72. Ikura Y, Morimoto H, Ogami M, Jomura H, Ikeoka N, Sakurai M. Expression of platelet-derived growth factor and its receptor in livers of patients with chronic liver disease. J Gastroenterol 1997; 32:496501.
73. Takeshi N, Soichiro M, Kiyoshi F, Nobuhiro O. role of platelets in chronic liver disease and acute liver injury. Hepatol res 2014; 44:165-172.
74. Hoshi R, Murata S, Matsuo R, Myronovych A, Hashimoto I, Ikeda H, Ohkohchi N. Freeze-dried platelets promote hepatocyte proliferation in mice. Cryobiology 2007; 55: 255-260.
75. Faiz Kabir Uddin Ahmed A, Ohtani H, Nio M, Funaki N, Iwami D, Kumagai S, et al. In situ expression of fibrogenic growth factors and their receptors in biliary atresia: Comparison between early and late stages. J Pathol 2000; 192:73-80.
76. Mormone E, George J, Nieto N. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact 2011; 193:225-231.
77. Oseini AM, Roberts LR PDGFralpha: A new therapeutic target in the treatment of hepatocellular carcinoma? Expert Opin Ther Targets 2009; 13:443-454.
78. Chen L, Shi Y, Jiang CY, Wei LX, Lv YL, Wang YL, Dai GH. Coexpression of PDGFr-alpha, PDGFr-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma. Int J Biol Markers 2011; 26:108-116.
79. Govaere O, Komuta M, Berkers J, Spee B, Janssen C, de Luca F, et al. Keratin 19: A key role player in the invasion of human hepatocellular carcinomas. Gut 2014; 63:674-685.
80. Patel SH, Kneuertz PJ, Delgado M, Kooby DA, Staley CA, 3rd, El-rayes BF, et al. Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma. Ann Surg Oncol 2011; 18:3384-3390.
81. Zhang J, Cao R, Zhang Y, Jia T, Cao Y, Wahlberg E. Differential roles of PDGFr-alpha and PDGFr-beta in angiogenesis and vessel stability. FASEB J 2009; 23: 153-163.
82. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9:685-693.
83. Roh JW, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, et al. Biologic effects of platelet-derived growth factor receptor alpha blockade in uterine cancer. Clin Cancer res 2014; 20:2740-2750.
84. Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2009; 50:604-620.
85. Tugues S, Fernandez-Varo G, Munoz-Luque J, ros J, Arroyo V, rodes J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007; 46: 1919-1926.
86. Cao R, Brakenhielm E, Li X, Pietras K, Widenfalk J, Ostman A, et al. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFr-alphaalpha and -alphabeta receptors. FASEB J 2002; 16:1575-1583.
87. Marx M, Perlmutter rA, Madri JA. Modulation of platelet-derived growth factor receptor expression in microvascular endothelial cells during in vitro angiogenesis. J Clin Invest 1994; 93:131-139.
88. Kitami Y, Inui H, Uno S, Inagami T. Molecular structure and transcriptional regulation of the gene for the platelet-derived growth factor alpha receptor in cultured vascular smooth muscle cells. J Clin Invest 1995; 96:558-567.
89. Zhu K, Pan Q, Zhang X, Kong L-QQ, Fan J, Dai Z, et al. Mir-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFrA expression. Carcinogenesis 2013; 34:2071-2079.
90. Zhang J-BB, Sun H-CC, Jia W-DD, Zhuang P-YY, Qian Y-BB, Zhu X-DD, et al. Up-regulation of platelet-derived growth factor-A is responsible for the failure of re-initiated interferon alpha treatment in hepatocellular carcinoma. BMC Cancer 2011; 12:439.
91. von Marschall Z, Scholz A, Cramer T, Schäfer G, Schirner M, Oberg K, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003; 95:437-448.
92. Ball SG, Shuttleworth CA, Kielty CM. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol 2007; 177:489-500.
93. Llovet JM, ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
94. Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013; 144:512-527.
95. Zijl FV, Mair M, Csiszar A, Schneller D, Zulehner G, Huber H, et al. Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene 2009.
96. Semela D, Das A, Langer D, Kang N, Leof E, Shah V. Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function. Gastro-enterology 2008; 135:671-679.
97. Moon J-OO, Welch TP, Gonzalez FJ, Copple BL. Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice. Am J Physiol Gastrointest Liver Physiol 2009; 296:92.
98. Copple BL, Bustamante JJ, Welch TP, Kim ND, Moon J-OO. Hypoxia-inducible factor-dependent production of profibrotic mediators by hypoxic hepatocytes. Liver Int 2009; 29:1010-1021.
99. Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, et al. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: An overview. J Transl Med 2010; 9:171.
100. Zhang X-F, Tan X, Zeng G, Misse A, Singh S, Kim Y, et al. Conditional β-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor α/phosphoinositide 3-kinase signaling. Hepatology 2010; 52:954-965.
101. Awuah PK, rhieu BH, Singh S, Misse A, Monga SP β-Catenin loss in hepatocytes promotes hepatocellular cancer after diethylnitrosamine and phenobarbital administration to mice. PLoS One 2011; 7.
102. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998; 95:8847-8851.
103. Colnot S, Decaens T, Niwa-Kawakita M, Godard C, Hamard G, Kahn A, et al. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci USA 2004; 101:17216-17221.
104. Nejak-Bowen K, Kikuchi A, Monga SP Beta-catenin-NF-kappaB interactions in murine hepatocytes: A complex to die for. Hepatology 2013; 57:763-774.
105. Chen WT, Zhu G, Pfaffenbach K, Kanel G, Stiles B, Lee AS GrP78 as a regulator of liver steatosis and cancer progression mediated by loss of the tumor suppressor PTEN. Oncogene 2014; 33:4997-5005.
106. Li Z, Wang Y, Wu H, Zhang L, Yang P, Li Z. GrP78 enhances the glutamine metabolism to support cell survival from glucose deficiency by modulating the β-catenin signaling. Oncotarget 2014; 5:5369-5380.
107. Vuorinen K, Ohlmeier S, Leppäranta O, Salmenkivi K, Myllärniemi M, Kinnula VL. Peroxiredoxin II expression and its association with oxidative stress and cell proliferation in human idiopathic pulmonary fibrosis. J Histochem Cytochem 2008; 56:951-959.
108. McGowan SE, McCoy DM. Fibroblasts expressing PDGF-receptor-alpha diminish during alveolar septal thinning in mice. Pediatr res 2011; 70:44-49.
109. Lindroos PM, rice AB, Wang YZ, Bonner JC. Role of nuclear factor-kappa B and mitogen-activated protein kinase signaling pathways in IL-1 beta-mediated induction of alpha-PDGF receptor expression in rat pulmonary myofibroblasts. J Immunol 1998; 161:3464-3468.
110. Moysidis SN, Thanos A, Vavvas DG. Mechanisms of inflammation in proliferative vitreoretinopathy: From bench to bedside. Mediators Inflamm 2011; 2012:815937.
111. Franziska van Z, Gudrun Z, Michaela P, Doris S, Christoph K, Mara H, et al. Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol 2009; 5: 1169-1179.
112. Fischer ANM, Fuchs E, Mikula M, Huber H, Beug H, Mikulits W. PDGF essentially links TGF-β signaling to nuclear β-catenin accumulation in hepatocellular carcinoma progression. Oncogene 2006; 26:3395-3405.
113. Zhou L, An N, Haydon rC, Zhou Q, Cheng H, Peng Y, et al. Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity. Cancer Lett 2003; 193:161-170.
114. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahe-patic cholangiocarcinoma: Systematic review and meta-analysis. JAMA Surg 2014.
115. Boonjaraspinyo S, Boonmars T, Wu Z, Loilome W, Sithithaworn P, Nagano I, et al. Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma. Tumour Biol 2012; 33:1785-1802.
116. Boonjaraspinyo S, Wu Z, Boonmars T, Kaewkes S, Loilome W, Sithithaworn P, et al. Overexpression of PDGFA and its receptor during carcinogenesis of Opisthorchis viverrini-associated cholangiocarcinoma. Parasitol Int 2012; 61: 145-150.
117. Thabut D, routray C, Lomberk G, Shergill U, Glaser K, Huebert R, et al. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology 2011; 54:573-585.
118. Lorusso PM, Eder JP. Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology. Expert Opin Investig Drugs 2008; 17:1013-1028.
119. Roskoski R. Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys res Commun 2007; 356:323328.
120. Abraham J, Chua YX, Glover JM, Tyner JW, Loriaux MM, Kilcoyne A, et al. An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma. Biochem Biophys res Commun 2012; 426:363-368.
121. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, Kitamura Y. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125:660-667.
122. rosmorduc O, Housset C. Hypoxia: A link between fibro-genesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis 2010; 30:258-270.
123. Fernandez M, Mejias M, Garcia-Pras E, Mendez R, Garcia-Pagan JC, Bosch J. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology 2007; 46:1208-1217.
124. reiberger T, Angermayr B, Schwabl P, rohr-Udilova N, Mitterhauser M, Gangl A, Peck-radosavljevic M. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol 2009; 51:865-873.
125. Shah GD, Loizos N, Youssoufian H, Schwartz JD, Rowinsky EK. Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha. Cancer 2010; 116:1018-1026.
126. Gerber DE, Gupta P, Dellinger MT, Toombs JE, Peyton M, Duignan I, et al. Stromal platelet-derived growth factor receptor alpha (PDGFralpha) provides a therapeutic target independent of tumor cell PDGFralpha expression in lung cancer xenografts. Mol Cancer Ther 2012; 11:2473-2482.
127. Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty B, et al. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target. Mol Cancer Ther 2005; 4: 369-379.
128. Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, et al. Platelet-derived growth factor receptor alpha (PDGFralpha) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol 2014; 132:166-175.
129. Takakura N, Yoshida H, Kunisada T, Nishikawa S, Nishikawa S-I. Involvement of platelet-derived growth factor receptor-alpha in hair canal formation. J Invest Dermatol 1996; 107:770-777.
130. Zymek P, Bujak M, Chatila K, Cieslak A, Thakker G, Entman ML, Frangogiannis NG. The role of platelet-derived growth factor signaling in healing myocardial infarcts. J Am Coll Cardiol 2006; 48:23152323.
131. Fruttiger M, Calver AR, Krüger WH, Mudhar HS, Michalovich D, Takakura N, et al. PDGF mediates a neuron-astrocyte interaction in the developing retina. Neuron 1996; 17:1117-1131.
132. Liao C-H, Akazawa H, Tamagawa M, Ito K, Yasuda N, Kudo Y, et al. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J Clin Invest 2010; 120:242-253.
133. Canbay A, Friedman S, Gores GJ Apoptosis: The nexus of liver injury and fibrosis. Hepatology 2004; 39:273-278.
134. Preisser L, Miot C, Le Guillou-Guillemette H, Beaumont E, Foucher ED, Garo E, et al. IL-34 and M-CSF are over-expressed in HCV fibrosis and induce pro-fibrotic macrophages which promote collagen synthesis by hepatic stellate cells. Hepatology 2014.
135. ross MA, Sander CM, Kleeb TB, Watkins SC, Stolz DB. Spatiotemporal expression of angiogenesis growth factor receptors during the revascularization of regenerating rat liver. Hepatology 2001; 34:1135-1148.
136. Grappone C, Pinzani M, Parola M, Pellegrini G, Caligiuri A, DeFranco R, et al. Expression of platelet-derived growth factor in newly formed cholangiocytes during experimental biliary fibrosis in rats. J Hepatol 1999; 31:100-109.